Improving Bioavailability & Solubility
Drug Development & delivery published on the virtual 2020 Global Drug Bioavailability Enhancement Summit, which this past December showcased novel
Tag: melphalan
Successful use of SBECD as vehicle in intravitreal treatment
A retrospective study based on data collected from Memorial Sloan-Kettering Cancer Center, New York shows high efficacy and low toxicity
Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)
National Medical Products Administration Approves Melphalan Hydrochloride For Injection (EVOMELA®, formulation based on SBECD aka. Captisol or Dexolve) as Treatment